Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: macker who wrote (254)	6/12/1998 9:09:00 AM
From: Gwolf	Read Replies (2) \| Respond to of 5402

Was Mr. Forthright actually Darth Vader in another life ? Gwolf

To: macker who wrote (254)	6/12/1998 9:30:00 AM
From: drdan	Read Replies (2) \| Respond to of 5402

well, if somategen got bought out at that price for a hemoglobin based produc, and i this product truly has the stated advantages over uch products, then this compaywill do very nicely.....

To: macker who wrote (254)	6/12/1998 11:16:00 AM
From: Andrew H	Read Replies (1) \| Respond to of 5402

>> for phase 1 you are correct, smtg never got to phase 1 and got bought out at 9<< LOL, macker do your homework, who ever told you SMTG never got to P1. Stop spreading such disinformation!!!! Shame on you!!!!

To: macker who wrote (254)	6/12/1998 11:47:00 AM
From: Andrew H	Read Replies (3) \| Respond to of 5402

This is the disinformation, macker, you say they never got to phase 1 Not only did they get to P1, they got through it and into P2. See the statement below from the 10K!!! >>for phase 1 you are correct, smtg never got to phase 1 and got bought out at 9 a share but was more fairly valued at 15, the lesser price was because the management was given shares of baxter to compensate<< In July 1996, Somatogen commenced an expanded Phase II trial in elective surgical patients in order to gather additional safety information as well as more comprehensive efficacy/activity information. The Phase II trial in the elective general surgical setting was discontinued after the termination of Somatogen's strategic alliance with Lilly. In April 1997, a Phase II trial was initiated by Somatogen to explore safety and preliminary efficacy in enhanced ANH in cardiac surgery. If the Phase II trial is successfully completed, the Company plans to undertake Phase III trials to establish safety and efficacy in a larger population of surgical patients to provide the basis for the filing of a Biologics License Application with the FDA.